Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137986 | 0.98 | SIGMAR1 (0.53) | EPHX1EPHX2SIGMAR1HDAC4HDAC1 | |
| SCHEMBL24021264 | 0.97 | EPHX1 (0.55) | EPHX1EPHX2SIGMAR1HDAC4HDAC1 | |
| SCHEMBL19019059 | 0.95 | EPHX1 (0.54) | EPHX1EPHX2SIGMAR1HDAC4HDAC1 | |
| SCHEMBL24021247 | 0.95 | EPHX1 (0.54) | EPHX1EPHX2SIGMAR1HDAC4HDAC1 | |
| SCHEMBL23137868 | 0.94 | SMN1; SMN2 (0.55) | EPHX1EPHX2SIGMAR1SMN1; SMN2 | |
| SCHEMBL19776084 | 0.93 | EPHX1 (0.46) | EPHX1EPHX2SIGMAR1 | |
| SCHEMBL19750307 | 0.93 | EPHX1 (0.46) | EPHX1EPHX2SIGMAR1 | |
| SCHEMBL18896225 | 0.92 | CA2 (0.49) | EPHX1EPHX2SIGMAR1 | |
| SCHEMBL13870548 | 0.87 | ALDH1A1 (0.46) | EPHX1EPHX2 | |
| SCHEMBL18896234 | 0.87 | SIGMAR1 (0.51) | EPHX1EPHX2SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | EPHX1 921/4885EPHX2 1997/4885SIGMAR1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.